Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers-Reference-Cited by-同舟云学术

Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers

Author:

Parikh Ravi B.¹²³⁴⁵,Min Eun Jeong⁶,Wileyto E. Paul⁷,Riaz Fauzia⁸⁹,Gross Cary P.⁹,Cohen Roger B.²³,Hubbard Rebecca A.⁷,Long Qi³⁷,Mamtani Ronac¹²³⁴⁵

Affiliation:

1. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia

2. Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia

3. Abramson Cancer Center, University of Pennsylvania, Philadelphia

4. Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia

5. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia

6. Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea

7. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia

8. Stanford University School of Medicine, Stanford, California

9. Cancer Outcomes Public Policy and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

Reference59 articles.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献